AstraZeneca ignores looming patent cliff to post positive Q3 results
This article was originally published in Scrip
Executive Summary
AstraZeneca's total revenue in the third quarter grew by 5% to $8.2 billion, despite its lead product Nexium (esomeprazole) posting a second successive quarter of decline in sales.